Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study | Zendy

Volkmar Müller | Zendy; Stefan Fuxius | Zendy; Claus-Christoph Steffens | Zendy; Christian Lerchenmüller | Zendy; Birgit Luhn | Zendy; Ursula VehlingKaiser | Zendy; Ursula Hurst | Zendy; Lars-Jörgen Hahn | Zendy; Ulrike Soeling | Zendy; Tim Wohlfarth | Zendy; Matthias Zaiß | Zendy

Open Access

Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study

Author(s) -

Volkmar Müller,

Stefan Fuxius,

Claus-Christoph Steffens,

Christian Lerchenmüller,

Birgit Luhn,

Ursula VehlingKaiser,

Ursula Hurst,

Lars-Jörgen Hahn,

Ulrike Soeling,

Tim Wohlfarth,

Matthias Zaiß

Publication year - 2014

Publication title -

oncology research and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.553

H-Index - 48

eISSN - 2296-5262

pISSN - 2296-5270

DOI - 10.1159/000369487

Subject(s) - capecitabine , medicine , hazard ratio , tolerability , quality of life (healthcare) , confidence interval , population , adverse effect , breast cancer , oncology , gastroenterology , cancer , colorectal cancer , nursing , environmental health

This non-interventional surveillance study (NIS) collected data on the quality of life (QoL) of patients treated with capecitabine as mono- or combination chemotherapy in an outpatient setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research